ArticleNature cell biology2021
ELOF1 is a transcription-coupled DNA repair factor that directs RNA polymerase II ubiquitylation.
Open access · bronzeAbstract read
In one paragraph
Article in Nature cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 104 citations in OpenAlex.
- Mechanism of spliceosome termination.Nature · 2026Article
- ERCC6 at the Transcription-Replication Interface: Integration of Transcription-Coupled Repair with Replication Stress Responses.International journal of molecular sciences · 2026Review
- Structural basis of nucleosome remodeling by Cockayne syndrome B homologue Komagataella phaffii Rad26.Nature communications · 2026Article
- Polymerase face-off: emerging concepts in transcription-replication coordination.EMBO reports · 2026Review
- Ubiquitin's code: UPS orchestrating DNA repair and genomic stability under genotoxic stress.Molecular and cellular biochemistry · 2026Review
- Finding novel vulnerabilities of hypomorphic BRCA1 alleles.Molecular oncology · 2026Article
- ELOF1 is a core component of the promoter-proximal paused RNA polymerase II complex.bioRxiv : the preprint server for biology · 2026Article
- Stabilization of AFF1 by PARylation ensures transcriptional restart after DNA damage.Nature chemical biology · 2026Article
- PAF1C restores transcription after DNA damage independently of promoting histone mark deposition.EMBO reports · 2026Article
- Integrator subunit INTS12 links ribotoxic stress to transcription-coupled nucleotide excision repair.Nature structural & molecular biology · 2026Article
- K63-linked ubiquitylation of S2P-RNAPII regulates transcription in a DNAPK inter-dependent manner in response to double-strand breaks.Nucleic acids research · 2026Article
- Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes.NAR cancer · 2026Article
- Mechanisms of transcription-coupled repair and DNA damage surveillance in health and disease.Nature reviews. Molecular cell biology · 2026Review
- The interaction of XPG with TFIIH through p62 and XPD is required for the completion of nucleotide excision repair.Nucleic acids research · 2026Article
- Article
- Hierarchical mechanisms control the clearance of DNA lesion-stalled RNA polymerase II.Nature communications · 2026Article
- Transcription quality control at the promoter-proximal checkpoint.Genes & development · 2025Review
- FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation.Science advances · 2025Article
- PARP1 and PARylation facilitate transcription-coupled DNA repair by stabilizing the CSB-RNAPII complex.Nucleic acids research · 2025Article
- Transcription-coupled repair: tangled up in convoluted repair.The FEBS journal · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 5 institutions in 3 countries.
Yana van der Weegen *Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Klaas de Lint *Department of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Diana van den HeuvelDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Yuka NakazawaDepartment of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan.
Tycho E T MevissenHoward Hughes Medical Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2324-5292
Janne J M van SchieDepartment of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Marta San Martin AlonsoDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Daphne E C BoerDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Román González-PrietoDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-8997-2321
Ishwarya V NarayananDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Noud H M KlaassenDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Annelotte P WondergemDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Khashayar RoohollahiDepartment of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Josephine C DorsmanDepartment of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Yuichiro HaraDepartment of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan.
Alfred C O VertegaalDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Job de LangeDepartment of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9002-8829
Johannes C WalterHoward Hughes Medical Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4186-7570
Sylvie M NoordermeerDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-2737-9690
Mats LjungmanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-1553-6695
Tomoo OgiDepartment of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-5492-9072
Rob M F WolthuisDepartment of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. r.wolthuis@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-3109-1588
Martijn S LuijsterburgDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. m.luijsterburg@lumc.nl.ORCID http://orcid.org/0000-0001-5796-6541
Leiden University Medical Center · NLNagoya University · JPHoward Hughes Medical Institute · USUniversity of Michigan · USUniversity of Amsterdam · NL
Funding
The Fanconi anemia pathway: role in DNA interstrand cross-link repairR01HL098316 · NHLBI · HARVARD MEDICAL SCHOOL · PI Johannes Walter · 2010 to 2026
$6.3MTargeting the RNA Exosome for Cancer TherapeuticsR01CA213214 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LJUNGMAN, MATS, NEAMATI, NOURI · 2019 to 2023
$2.4MMapping of Novel Candidate Functional Elements with Bru-Seq TechnologyUM1HG009382 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LJUNGMAN, MATS · 2017 to 2021
$2.3MHoward Hughes Medical InstituteNCI NIH HHS R01 CA213214NHGRI NIH HHS UM1 HG009382NHLBI NIH HHS R01 HL098316
Abstract
Cells employ transcription-coupled repair (TCR) to eliminate transcription-blocking DNA lesions. DNA damage-induced binding of the TCR-specific repair factor CSB to RNA polymerase II (RNAPII) triggers RNAPII ubiquitylation of a single lysine (K1268) by the CRL4
Indexed as
DNA DamageDNA RepairUbiquitinationCell Line, TumorCRISPR-Cas SystemsDNA HelicasesDNA Repair EnzymesHumansPeptide Elongation Factor 1Poly-ADP-Ribose Binding ProteinsProtein BindingProtein Interaction Domains and MotifsReceptors, Interleukin-17RNA Polymerase IITranscription Elongation, GeneticTranscription FactorsDNA HelicasesDNA Repair EnzymesERCC6 protein, humanERCC8 protein, humanIL17RB protein, humanPeptide Elongation Factor 1Poly-ADP-Ribose Binding ProteinsReceptors, Interleukin-17RNA Polymerase IITranscription FactorsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.